Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Wim Janssens, M.D."'
Autor:
Laurens Liesenborghs, M.D., Isabel Spriet, Pharm.D., Dirk Jochmans, Ph.D., Ann Belmans, Ph.D., Iwein Gyselinck, M.D., Laure-Anne Teuwen, M.D., Sebastiaan ter Horst, Msc., Erwin Dreesen, Ph.D., Tatjana Geukens, M.D., Matthias M. Engelen, M.D., Ewout Landeloos, M.D., Vincent Geldhof, M.D., Helga Ceunen, Barbara Debaveye, Bert Vandenberk, M.D., Lorenz Van der Linden, Pharm.D., Sofie Jacobs, MSc., Lana Langendries, Msc., Robbert Boudewijns, Msc., Thuc Nguyen Dan Do, Msc., Winston Chiu, Msc., Xinyu Wang, Msc., Xin Zhang, Msc., Birgit Weynand, M.D., Thomas Vanassche, M.D., Timothy Devos, M.D., Geert Meyfroidt, M.D., Wim Janssens, M.D., Robin Vos, M.D., Pieter Vermeersch, M.D., Joost Wauters, M.D., Geert Verbeke, Ph.D., Paul De Munter, M.D., Suzanne J.F. Kaptein, Ph.D, Joana Rocha-Pereira, Ph.D., Leen Delang, Ph.D., Eric Van Wijngaerden, M.D., Johan Neyts, Ph.D., Peter Verhamme, M.D.
Publikováno v:
EBioMedicine, Vol 66, Iss , Pp 103288- (2021)
Background: The antifungal drug itraconazole exerts in vitro activity against SARS-CoV-2 in Vero and human Caco-2 cells. Preclinical and clinical studies are required to investigate if itraconazole is effective for the treatment and/or prevention of
Externí odkaz:
https://doaj.org/article/493cb36c411d448c91da9bf02c9c911c
